Mesothelium expression of vascular cell adhesion molecule‐1 (VCAM‐1) is associated with an unfavorable prognosis in epithelial ovarian cancer (EOC)

Abstract

Background Mesothelium VCAM-1 expression in the metastatic epithelial ovarian cancer (EOC) microenvironment is induced by tumor and mediates tumor cell invasion. VCAM-1 imaging suggests expression during treatment is an indicator of platinum resistance. Here, we assess the potential prognostic significance of mesothelium VCAM-1 expression and prospectively evaluate whether soluble VCAM-1 (sVCAM-1) is a surrogate for mesothelium expression. Methods A retrospective review of EOC patients was performed to evaluate outcomes with mesothelium VCAM-1 expression determined by immunohistochemistry of peritoneum or omentum specimens. A prospective cohort of EOC patients was identified and followed through primary treatment. Serum for sVCAM-1 evaluation, determined by ELISA, was collected prior to surgery or neoadjuvant chemotherapy and at each treatment cycle. Peritoneal specimens were obtained during debulking to assess mesothelial VCAM-1 expression. Results Retrospective review identified 54 advanced stage EOC patients. Patients expressing mesothelium VCAM-1 had shortened overall (44 vs 79 months, p=0.035) and progression-free survival (18 vs 67 months, p=0.010); median time to platinum-resistance was 36 months for VCAM-1 expressing patients and not yet determined for the VCAM-1 negative group. In our prospective observational cohort, eighteen EOC patients completed primary treatment; 3 were negative for mesothelium VCAM-1 expression, and sVCAM-1 did not vary between groups. Conclusions Mesothelium VCAM-1 expression negatively associates with progression-free and overall survival in EOC. This is especially compelling in light of prior data suggesting that persistent VCAM-1 expression during treatment is an indicator of platinum resistance. Our pilot study had insufficient cases to determine whether sVCAM-1 would substitute for mesothelium expression.

Tissue and plasma levels of galectins in patients with high grade serous ovarian carcinoma as new predictive biomarkers

“…3D ), it is important to note that because of the limited number of patients used in this study, we considered chemoresistance as a relapse within 2-years post-chemotherapy treatment. Chemoresistance is often characterized as a relapse during the 6 months following the last chemotherapy treatment 45 , although longer periods of time have also been associated with increased chemoresistance 46 , 47 . Future studies using larger cohorts of patients will be needed to correlate expression of galectin signatures with a specific treatment and ideally a single agent will thus be needed to confirm our results using other criteria of chemoresistance.…”

Lentiviral CRISPR/Cas9 nickase vector mediated BIRC5 editing inhibits epithelial to mesenchymal transition in ovarian cancer cells

“…Moreover, ovarian cancers primarily metastasize through peritoneal dissemination from the primary tumor site to other distant organs including the omentum, colon, and liver. This metastatic process is often accompanied by ascitic fluid accumulation, which is associated with tumor metastasis and chemoresistance, further contributing to a poor survival rate in patients [ 2 , 3 ]. The current clinical therapy is to perform debulking surgery followed by chemotherapy [ 4 ].…”

High Preoperative Serum sVCAM-1 Concentration as a Predictor of Early Ovarian Cancer Recurrence

“…suggested VCAM-1 as indicator for ovarian cancer response to platinum based chemotherapy, 11 and in a recent study, correlated serum sVCAM-1 with mesothelial VCAM-1 expression in 18 patients with ovarian cancer and were unable to identify serum sVCAM-1 as a surrogate for mesothelium expression. 12 To the best of our knowledge we didn't find any studies concerning sVCAM-1 and ovarian cancer recurrence. The role VCAM-1 in ovarian cancer is largely unclear, but it has been shown that mesothelial expression mediates tumor cell invasion.…”